297 related articles for article (PubMed ID: 34232223)
21. Hyperlipoproteinaemia(a) - apheresis and emerging therapies.
Vogt A
Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):12-17. PubMed ID: 28185213
[TBL] [Abstract][Full Text] [Related]
22. Considerations for routinely testing for high lipoprotein(a).
Nurmohamed NS; Moriarty PM; Stroes ES
Curr Opin Lipidol; 2023 Aug; 34(4):174-179. PubMed ID: 35942815
[TBL] [Abstract][Full Text] [Related]
23. Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation.
Hoogeveen RC; Ballantyne CM
Clin Chem; 2021 Jan; 67(1):143-153. PubMed ID: 33257928
[TBL] [Abstract][Full Text] [Related]
24. Proprotein convertase subtilisin/kexin type 9 inhibitors and lipoprotein(a)-mediated risk of atherosclerotic cardiovascular disease: more than meets the eye?
Boffa MB; Koschinsky ML
Curr Opin Lipidol; 2019 Dec; 30(6):428-437. PubMed ID: 31577611
[TBL] [Abstract][Full Text] [Related]
25. Lipoprotein(a) Reduction With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-analysis.
Farmakis I; Doundoulakis I; Pagiantza A; Zafeiropoulos S; Antza C; Karvounis H; Giannakoulas G
J Cardiovasc Pharmacol; 2021 Mar; 77(3):397-407. PubMed ID: 33298738
[TBL] [Abstract][Full Text] [Related]
26. PCSK9 Inhibition with alirocumab increases the catabolism of lipoprotein(a) particles in statin-treated patients with elevated lipoprotein(a).
Watts GF; Chan DC; Pang J; Ma L; Ying Q; Aggarwal S; Marcovina SM; Barrett PHR
Metabolism; 2020 Jun; 107():154221. PubMed ID: 32240727
[TBL] [Abstract][Full Text] [Related]
27. Emerging therapeutic agents to lower lipoprotein (a) levels.
Kolski B; Tsimikas S
Curr Opin Lipidol; 2012 Dec; 23(6):560-8. PubMed ID: 23041907
[TBL] [Abstract][Full Text] [Related]
28. PCSK9 targets important for lipid metabolism.
Schulz R; Schlüter KD
Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):2-11. PubMed ID: 28176216
[TBL] [Abstract][Full Text] [Related]
29. Lipoprotein(a) and Atherosclerotic Cardiovascular Disease, the Impact of Available Lipid-Lowering Medications on Lipoprotein(a): An Update on New Therapies.
Tsushima T; Tsushima Y; Sullivan C; Hatipoglu B
Endocr Pract; 2023 Jun; 29(6):491-497. PubMed ID: 36563785
[TBL] [Abstract][Full Text] [Related]
30. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
[TBL] [Abstract][Full Text] [Related]
31. Use of Low-Density Lipoprotein-Lowering Therapies Before and After PCSK9 Inhibitor Initiation.
Rymer JA; Mues KE; Monda KL; Bratton EW; Wirtz HS; Okerson T; Overman RA; Brookhart MA; Muntner P; Wang TY
J Am Heart Assoc; 2020 May; 9(9):e014347. PubMed ID: 32326795
[TBL] [Abstract][Full Text] [Related]
32. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.
Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G
Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202
[TBL] [Abstract][Full Text] [Related]
33. Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a).
Stiekema LCA; Prange KHM; Hoogeveen RM; Verweij SL; Kroon J; Schnitzler JG; Dzobo KE; Cupido AJ; Tsimikas S; Stroes ESG; de Winther MPJ; Bahjat M
Eur Heart J; 2020 Jun; 41(24):2262-2271. PubMed ID: 32268367
[TBL] [Abstract][Full Text] [Related]
34. Antisense Oligonucleotides Targeting Lipoprotein(a).
Langsted A; Nordestgaard BG
Curr Atheroscler Rep; 2019 May; 21(8):30. PubMed ID: 31111240
[TBL] [Abstract][Full Text] [Related]
35. What do we know about the role of lipoprotein(a) in atherogenesis 57 years after its discovery?
Cybulska B; Kłosiewicz-Latoszek L; Penson PE; Banach M
Prog Cardiovasc Dis; 2020; 63(3):219-227. PubMed ID: 32277995
[TBL] [Abstract][Full Text] [Related]
36. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
Rosenblit PD
Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
[TBL] [Abstract][Full Text] [Related]
37. Emerging Pharmacotherapy to Reduce Elevated Lipoprotein(a) Plasma Levels.
Eraikhuemen N; Lazaridis D; Dutton MT
Am J Cardiovasc Drugs; 2021 May; 21(3):255-265. PubMed ID: 32929693
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic Agents Targeting Cardiometabolic Risk for Preventing and Treating Atherosclerotic Cardiovascular Diseases.
Arsenault BJ; Perrot N; Puri R
Clin Pharmacol Ther; 2018 Aug; 104(2):257-268. PubMed ID: 29737015
[TBL] [Abstract][Full Text] [Related]
39. Relationship between "LDL-C", estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide.
Viney NJ; Yeang C; Yang X; Xia S; Witztum JL; Tsimikas S
J Clin Lipidol; 2018; 12(3):702-710. PubMed ID: 29574075
[TBL] [Abstract][Full Text] [Related]
40. Lipoprotein(a) - Marker for cardiovascular risk and target for lipoprotein apheresis.
Klingel R; Heigl F; Schettler V; Roeseler E; Grützmacher P; Hohenstein B; Vogt A; Fassbender C; Heibges A; Julius U
Atheroscler Suppl; 2019 Dec; 40():17-22. PubMed ID: 31818445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
